TG Therapeutics, Inc. (TGTX) Earnings History
Profitable30 years of earnings data (1996–2025) · Positive TTM net income
Loading earnings history...
TG Therapeutics, Inc. (TGTX) Earnings Overview
As of June 23, 2026, TG Therapeutics, Inc. (TGTX) reported trailing twelve-month net income of $462M, reflecting +1746.7% year-over-year growth. The company earned $2.89 per diluted share over the past four quarters, with a net profit margin of 72.6%.
Looking at the long-term picture, TGTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $447M in fiscal 2025, representing a new all-time high.
TG Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 83.7%, operating margin of 20.0%, and net margin of 72.6%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), IMVT (-$506M net income), PRAX (-$327M net income), TGTX has outperformed on profitability metrics. Compare TGTX vs RCUS →
TGTX Earnings vs Peers
Earnings metrics vs comparable public companies
TGTX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $447M | +1812.4% | $123M | $2.77 | 72.6% | 20.0% |
| 2024 | $23M | +84.5% | $42M | $0.15 | 7.1% | 12.7% |
| 2023 | $13M | +105.7% | $21M | $0.09 | 5.4% | 8.8% |
| 2022 | -$224M | +35.7% | -$218M | $-1.46 | -8036.3% | -7839.0% |
| 2021 | -$348M | -24.6% | -$345M | $-2.63 | -5204.1% | -5154.3% |
| 2020 | -$279M | -61.6% | -$274M | $-2.42 | -183803.3% | -179996.1% |
| 2019 | -$173M | +0.4% | -$169M | $-1.96 | -113730.9% | -111220.4% |
| 2018 | -$173M | -46.4% | -$174M | $-2.30 | -114132.9% | -114736.8% |
| 2017 | -$118M | -51.4% | -$119M | $-1.91 | -77749.9% | -77904.6% |
| 2016 | -$78M | -24.3% | -$79M | $-1.60 | -51353.4% | -51823.5% |
| 2015 | -$63M | -12.8% | -$63M | $-1.38 | -41310.0% | -41461.9% |
| 2014 | -$56M | -172.4% | -$56M | $-1.64 | -36606.5% | -36567.0% |
| 2013 | -$20M | -13.3% | -$23M | $-0.81 | -13438.8% | -15071.4% |
| 2012 | -$18M | -2018.5% | -$27M | $-1.38 | -94879.9% | -141196.4% |
| 2011 | $-853,074 | -236.8% | $-881,974 | $-0.44 | - | - |
| 2010 | $623,645 | +122.3% | -$2M | $15.68 | - | - |
| 2009 | -$3M | +34.6% | -$2M | $-111.24 | - | - |
| 2008 | -$4M | +64.5% | -$4M | $-170.00 | - | - |
| 2007 | -$12M | -24.1% | -$12M | $-497.55 | - | - |
| 2006 | -$10M | +49.3% | -$10M | $-453.62 | - | - |
| 2005 | -$19M | -224.6% | -$19M | $-1236.34 | - | - |
| 2004 | -$6M | +1.1% | -$6M | $-615.64 | - | - |
| 2003 | -$6M | -285.3% | -$5M | $-748.86 | - | - |
| 2002 | -$2M | +10.8% | -$2M | $-347.70 | -309.4% | -310.6% |
| 2001 | -$2M | +70.1% | -$3M | $-1528.59 | -64.0% | -114.6% |
| 2000 | -$6M | -141.8% | -$3M | $-13339.03 | -108.3% | -59.0% |
| 1999 | -$2M | +14.3% | -$3M | $-7017.54 | -200.0% | -225.0% |
| 1998 | -$3M | +46.2% | -$3M | $-8750.00 | -93.3% | -90.0% |
| 1997 | -$5M | -44.4% | -$5M | $-23853.21 | -5200.0% | -5300.0% |
| 1996 | -$4M | - | -$4M | $-17391.30 | -3600.0% | -3800.0% |
Download Data
Export TGTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TGTX — Frequently Asked Questions
Quick answers to the most common questions about buying TGTX stock.
What is TGTX earnings per share (EPS)?
TGTX trailing twelve-month (TTM) diluted EPS is $2.89, reflecting +1746.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1996 to 2025 is available in the table on this page.
What is TG Therapeutics, Inc.'s net income?
TG Therapeutics, Inc. (TGTX) trailing twelve-month net income is $462M as of 2025. Earnings grew +1746.7% year-over-year. TG Therapeutics, Inc. has been profitable for 3 consecutive years.
Is TGTX profitable?
Yes, TGTX is profitable with a TTM net income of $462M and a net profit margin of +72.6%. TG Therapeutics, Inc. has generated profits for 3 consecutive years.
What is TGTX's earnings growth rate?
TGTX compound annual EPS growth rates (CAGR): 1-Year: +1746.7%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1996 to 2025.
What are TGTX's profit margins?
TG Therapeutics, Inc. net profit margin is +72.6%, operating margin is +20.0%, and gross margin is +83.7%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +102.8%.
Is TGTX growing earnings?
Yes, TGTX earnings are accelerating — EPS growth of +1746.7% exceeds the 5-year CAGR of N/A. TTM net income reached $462M. Earnings momentum is strengthening.
What was TGTX's best earnings year?
TG Therapeutics, Inc.'s highest annual net income on record is $447M, achieved in fiscal year 2025. Earnings history on this page spans 1996 to 2025 and includes all annual and quarterly figures.
What were TGTX's earnings last quarter?
TGTX's most recent reported quarter was Q1 2026. Net income was $20M with diluted EPS of $0.12. For a full breakdown of all quarters, see the quarterly earnings table on this page.